Tag Archives: Johnson & Johnson

Johnson & Johnson Slammed Over Manufacturing Practices, Phantom Recall

By Oriana Schwindt | Published: June 2, 2010
In 1982, Johnson & Johnson garnered an enduring amount of goodwill when, seemingly without any thought of lost profit, it immediately yanked Tylenol from the shelves nationwide after learning someone was slipping cyanide into bottles in Chicago. The company’s sure and swift PR response became the model for crisis management for the corporate world. But in [...]
Posted in Corporate Responsibility | Also tagged , , , , , , , , , | Leave a comment

A Critical Path to New TB Treatments

By George Koroneos | Published: March 18, 2010
Image via Wikipedia FDA Commissioner Margaret Hamburg announced, on Thursday, a new joint initiative between industry, FDA, and non-profit organizations designed to fast-track modern combination treatments for tuberculosis. Where once it took more than two decades to create new therapies for TB, this collaboration is expected to produce working treatments in less than six years, providing [...]
Posted in R&D | Also tagged , , , , , , | 2 Comments

Pharma and Haiti: Can Altruism Backfire?

By Pharm Exec | Published: January 25, 2010
Guest blog by Pharm Exec Europe’s Jacky Law. Pharma companies are responding swiftly to the recent earthquake in Haiti with millions of dollars in cash and drugs. GlaxoSmithKline boasted, for example, that its initial $1.2 million offering of medicines — mainly oral and topical antibiotics — was on the first airlift to the Caribbean island and [...]
Posted in Corporate Responsibility, Global, Guest Blog, News | Also tagged , , , , | Leave a comment

Feds Chase Down Faulty Skincare Promos

By George Koroneos | Published: August 26, 2009
FDA’s Division of Drug Marketing Communications, this week, posted a slew of warning and untitled letters to pharma firms for misleading skincare advertisements. Johnson & Johnson, Galderma, and Allergan each received a letter documenting complaints ranging from false advertising to unsubstantial efficacy claims. J&J received a violation letter in response to a journal ad for its [...]
Posted in FDA, Marketing | Also tagged , , , | 1 Comment

Merck/Schering-Plough Merger Highlights (Update 1)

By George Koroneos | Published: March 9, 2009
Merck and Schering-Plough’s CEOs are giving a run down of the benefits of the $41.1 billion merger, announced this morning, in a conference call with investors. Here are some of the highlights: • Total price of the sale will be $41.1 billion or $23.6 per Schering share. • This deal is structured as a reverse merger with [...]
Posted in Deals, Strategy | Also tagged , , , , , | 4 Comments